One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...
Vertex has secured a label expansion through the FDA's Commis | Vertex Pharmaceuticals has gained a label expansion from the ...
In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
Morning Overview on MSN
The first baby treated with a custom CRISPR therapy is thriving a year later
One year after receiving three doses of a custom-built CRISPR base-editing therapy at Children’s Hospital of Philadelphia, ...
In late June 2026, CRISPR Therapeutics AG was added to several Russell growth indexes, including the Russell 2000 Growth, ...
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
A team of researchers led by Professor Akitsu Hotta (Department of Clinical Application) developed a comprehensive framework ...
9d
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results